SEC Form 4 · accession 0001140361-16-070511
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lana Elizabeth Janes
Officer — Sr. Vice Pres. - See Remarks
Period of report
Jun 17, 2016
Accepted (ET)
Jun 21, 2016 · 9:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $1.43 | Jun 17, 2016 | A | 220,000 | A | — | Jun 17, 2026 | Common stock | 220,000 | 220,000 | D |
| Restricted Stock UnitsF3,F4,F5 | — | Jun 17, 2016 | A | 60,000 | A | — | — | Common stock | 60,000 | 60,000 | D |
Explanation of responses
- F1Option exercise price reflects the closing price of the Issuer's common stock on the NASDAQ Stock Market on the June 17, 2016 grant date.
- F2The options vest and become exercisable in thirty-six (36) successive and equal monthly installments from the June 17, 2016 grant date. These options were awarded pursuant to the Issuer's 2000 Incentive Stock Plan, as amended and restated (the "2000 Plan").
- F3Each Restricted Stock Unit ("RSU") represents a right to receive one share of common stock of the Issuer upon vesting.
- F4The RSUs vest in installments, with 40,000 RSUs vesting on the first anniversary from the June 17, 2016 grant date, and the remaining 20,000 RSUs vesting on the second anniversary from the June 17, 2016 grant date. These RSUs were awarded pursuant to the 2000 Plan.
- F5The RSUs have no fixed expiration date.
Remarks
The title of the Reporting Person is Senior Vice President, Intellectual Property and Technology Development, and Chief Patent Officer.